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Hypoxia Inducible Factor-1a in Osteochondral
Tissue Engineering
Dheraj K. Taheem, PhD,1 Gavin Jell, PhD,2 and Eileen Gentleman, PhD1
Damage to osteochondral (OC) tissues can lead to pain, loss of motility, and progress to osteoarthritis. Tissue
engineering approaches offer the possibility of replacing damaged tissues and restoring joint function; however,
replicating the spatial and functional heterogeneity of native OC tissue remains a pressing challenge. Chon-
drocytes in healthy cartilage exist in relatively low-oxygen conditions, while osteoblasts in the underlying bone
experience higher oxygen pressures. Such oxygen gradients also exist in the limb bud, where they influence OC
tissue development. The cellular response to these spatial variations in oxygen pressure, which is mediated by
the hypoxia inducible factor (HIF) pathway, plays a central role in regulating osteo- and chondrogenesis by
directing progenitor cell differentiation and promoting and maintaining appropriate extracellular matrix pro-
duction. Understanding the role of the HIF pathway in OC tissue development may enable new approaches to
engineer OC tissue. In this review, we discuss strategies to spatially and temporarily regulate the HIF pathway
in progenitor cells to create functional OC tissue for regenerative therapies.
Keywords: HIF-1a, hypoxia, cartilage, osteochondral tissue engineering
Impact Statement
Strategies to engineer osteochondral (OC) tissue are limited by the complex and varying microenvironmental conditions in
native bone and cartilage. Indeed, native cartilage experiences low-oxygen conditions, while the underlying bone is
relatively normoxic. The cellular response to these low-oxygen conditions, which is mediated through the hypoxia inducible
factor (HIF) pathway, is known to promote and maintain the chondrocyte phenotype. By using tissue engineering scaffolds
to spatially and temporally harness the HIF pathway, it may be possible to improve OC tissue engineering strategies for the
regeneration of damaged cartilage and its underlying subchondral bone.
Introduction
Cartilage has a poor capacity for self-repair after in-jury, which can lead to joint pain, immobility, and
eventually osteoarthritis (OA). By repairing cartilage, it may
be possible to restore joint function and prevent the devel-
opment of OA. Tissue engineering (TE), a field whose pri-
mary aim is to form new tissue,1 has the potential to
revolutionize treatments for cartilage damage. Native car-
tilage’s primary function is to cushion bones and support the
smooth movement of articular joints. Cartilage achieves this
by seamlessly integrating with its underlying bone. There-
fore, cartilage TE strategies often aim to engineer bone and
cartilage together to create osteochondral (OC) constructs
that can integrate with the supportive subchondral bone.
However, engineering such disparate tissues in a single TE
construct is challenging as cartilage is dominated by a col-
lagen type II/proteoglycan-rich matrix with embedded
chondrocytes, while the underlying bone comprises a min-
eralized collagen type I structure that is maintained by os-
teocytes. However, fundamental to both the development
and maintenance of native OC tissue is oxygen pressure.
Oxygen pressure is low in native cartilage, but higher in
subchondral bone. The cellular response to oxygen pressure,
which is mediated by the hypoxia inducible factor (HIF)
pathway, is central in controlling the differentiation of pro-
genitor cells during development, their production of appro-
priate extracellular matrix (ECM), and maintenance of their
correct phenotype. Therefore, by creating TE scaffolds that
can spatially harness the cellular response to oxygen pressure,
it may be possible to effectively engineer functional OC tis-
sue. In this study, we review the role of the HIF pathway in
OC development and maintenance and discuss its potential
for use in OC TE.
1Centre for Craniofacial and Regenerative Biology, King’s College London, London, United Kingdom.
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The Effect of Oxygen Pressure and the HIF Pathway
in OC Tissue Development and Maintenance
The cellular response to oxygen plays an important role in
both the development and maintenance of OC tissue2–7 and
is primarily mediated through the HIF pathway (Fig. 1).
Under normoxic conditions, HIF-1a, the oxygen-responsive
subunit of the HIF complex, is continually degraded.
However, under hypoxic conditions, HIF-1a accumulates
within the cytoplasm and translocates to the nucleus where it
regulates expression of target (hypoxia-responsive element,
HRE) genes. Moreover, hypoxia enhances the binding be-
tween HIF-1a and its transcriptional cofactors, which fur-
ther augments HIF complex-mediated regulation of gene
expression.8 During development, the HIF pathway plays
fundamental roles in directing the differentiation of OC
progenitors. In general, increased HIF-1a stabilization (un-
der low-oxygen conditions) stimulates a prochondrogenic,
antiosteogenic, and antihypertrophic transcriptome.9 This
effect is reversed in the presence of higher oxygen con-
centrations as HIF-1a is degraded, which promotes a more
hypertrophic/osteoblastic fate.
The Role of HIF-1a in Differentiation of OC Progenitor
Cells, Their Survival, and Phenotypic Maintenance
During development, articular cartilage forms during en-
dochondral ossification,10 the process by which the axial
skeleton is created. To achieve this, a condensed population of
mesenchymal precursors form the initial cartilaginous anlage,
which is subsequently infiltrated by the vasculature and ossi-
fied.11 Concomitant with this process, cartilage ismaintained at
the ends of long bones and within it, a population of chon-
drocytes, which will go on to form the articular cartilage. HIF-
1a is essential in this process as under the low-oxygen condi-
tions of the developing growth plate, knockdown of HIF-1a
results in chondrocyte cell death.2Moreover, knockdown of the
enzyme required for HIF-1a degradation in the growth plate
deregulates mesenchymal precursor and chondrocyte prolif-
eration12,13 and its conditional inactivation in the developing
mouse limb bud mesenchyme negatively impacts both the
formation of cartilage and joint development.7WhenHIF-1a is
conditionally inactivated, expression of SOX9, the master
transcriptional regulator of chondrogenesis, and its down-
stream targets, the genes that encode collagen type II and ag-
grecan, the main constituents of cartilage tissue, are all
reduced.7,9 In vitro activation of the HIF pathway has similarly
been shown to upregulate SOX9 expression and that of its
downstream targets in murine14 and rat15 mesenchymal stro-
mal cells (MSCs) as well as in human articular chondrocytes
(hACs).16 Furthermore, engineering murine MSCs to stably
express HIF-1a under normoxic conditions has been shown to
potentiate their BMP2-induced chondrogenic differentiation.17
In addition to driving the differentiation of progenitors,
hypoxia and HIF-1a also play a role in maintaining cells’
chondrogenic phenotypes by preventing their hypertrophic
or osteogenic differentiation. During endochondral ossifica-
tion, signaling gradients, including those triggered by oxygen
pressure, are responsible for retaining populations of chon-
drocytes in their nonhypertrophic state, priming them for a
permanent, articular chondrocyte fate.18 Hypoxia and HIF-1a
achieve this in hACs by downregulating the expression of
hypertrophic fibroblast-like markers such as COL1A1 and
COL3A1.19 Moreover, hypoxia suppresses the expression of
matrixmetalloproteinases (MMPs) and aggrecanases in hACs,
FIG. 1. HIF pathway-
mediated regulation of OC
progenitor cells. Under hyp-
oxic conditions, the HIF com-
plex binds to its response
elements (HREs) on target
genes (A) where it acts to en-
hance SOX9 expression and
activity (B), resulting in in-
creased production of cartilage
ECM (C), dampened activity
of RUNX2 (D), and reduced
expression of genes involved
in osteogenesis (E) and chon-
drocyte hypertrophy (F). HIF
has also been shown to in-
crease expression of glycolytic
enzymes (G) as well as Wnt
antagonists involved in delay-
ing chondrocyte hypertrophy
(H). Yellow arrows indicate
pathways/genes that are acti-
vated, while red arrows show
pathways/genes that are in-
hibited under hypoxic condi-
tions. ECM, extracellular
matrix; HIF, hypoxia inducible
factor; HRE, hypoxia-
responsive element; OC, os-
teochondral. Color images are
available online.
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both of which degrade the cartilagematrix.20 Similarly, human
and other mammalian cartilage explants cultured under hyp-
oxic conditions show HIF-1a-mediated suppression of carti-
lage catabolism by a disintegrin and metalloproteinase with
thrombospondin motifs (ADAMTS-5) and MMP-13.21 The
ability of HIF signaling to promote a stable articular phenotype
is also supported by observations that hypoxia enhances the
expression of antihypertrophic Wnt antagonists,22 and HIF-1a
conditional knockout in developing cartilage results in reduced
expression of Wnt9a and GDF5.9
The Role of HIF-1a in Cartilage ECM Formation
Not only do physiological hypoxia and the HIF pathway
play important roles in regulating the differentiation of OC
progenitor cells but they also appear to drive the formation
of appropriate ECM. The ECM of native cartilage is dom-
inated by a combination of collagen type II and proteogly-
cans, and hypoxia and the HIF pathway have been shown to
regulate the formation of this matrix (Fig. 2). For example,
physiological hypoxia enhances the production of cartilage-
specific ECM in cultured hACs when compared with that
formed under normoxic conditions.23 Similarly, hACs in
pellet cultures synthesize collagen fibrils with more ordered
morphologies when cultured in 5% oxygen compared with
under normoxic conditions.16,21,23 Similar observations have
been made in chondrocytes embedded in alginate hydro-
gels24 and seeded on 3D PLGA scaffolds.25 Moreover, hu-
man bone marrow-derived MSCs and hACs pretreated with
hypoxia before encapsulation in alginate and implantation in
a nude mouse model showed enhanced cartilage ECM for-
mation compared with that observed when cells were pre-
cultured under normoxic conditions.26
Regulation of ECM synthesis is dependent on the activity
of HIF-1a as its conditional knockdown in developing murine
limbs results in abnormal ECM morphology as well as re-
duced production of proteoglycans and collagen type II in the
growth plate.7,9,27 Similarly, stabilizing HIF-1a chemically
by inhibiting its ubiquitination and degradation causes hACs
to increase their secretion of collagen type II and aggrecan.28
Hypoxia has also been shown to increase cartilage-like ECM
production in MSCs.29 Indeed, delivery of a HIF-1a expres-
sion vector enhances the expression of genes for both colla-
gen type II and the proteoglycan aggrecan, as well as a panel
of chondrogenic transcription factors.26 Moreover, stabiliza-
tion of HIF-1a promotes the formation of cartilage-specific
ECM by both upregulating the expression of SOX9 and
through post-translational modifications to collagen type II.30
HIF-1a’s role in regulating ECM production is thought to be
mediated by its regulation of collagen prolyl 4-hydroxylase,
which is required for the addition of 4-hydroxyproline resi-
dues to collagen fibrils, allowing them to form triple heli-
ces.30 In addition, the HIF pathway is also thought to control
expression of lysyl oxidase, an enzyme required for the cross-
linking of collagen triple helices.31,32
Strategies for OC TE
A common approach to engineer cartilage tissue is to mi-
mic aspects of the native, in vivo cellular microenvironment
FIG. 2. Oxygen, HIF-1a, transcription factor, and ECM gradients in OC tissue. Oxygen pressure is low in native cartilage,
but high in the subchondral bone. The cellular response to these varying oxygen pressures, which are mediated by HIF-1a,
plays a role in regulating transcription factors important in progenitor cell differentiation toward chondrogenic and osteo-
genic phenotypes and in promoting the production of proteins that are abundant in cartilage compared with bone. (a) A
histological section of the OC tissue from a rabbit metacarpophalangeal joint stained with hematoxylin, Safranin O, and fast
green. Cartilage appears red, calcified cartilage appears dark green, and bone appears blue. Image is adapted from106 (CC-BY
2.0). (b)A schematic of OC tissue showing expression gradients of HIF-1a, transcription factors, proteins, and enzymes. Factors
in blue are upregulated or promoted in response to low oxygen pressures, while those in red are downregulated.2,107–112 col II,
collagen type II; acan, aggrecan; col I, collagen type I; col X, collagen type X. Color images are available online.
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in 3D scaffolds seeded with appropriate progenitor cells.33–35
A clinical example of this is matrix-assisted, autologous
chondrocyte transplantation/implantation (MACT/MACI),
which involves seeding autologous chondrocytes in a 3D
scaffold before surgical implantation. However, despite
providing chondrocytes with a 3D environment,36 the MACT
matrix often does not adequately mimic many microenvi-
ronmental conditions within native cartilage, including local
oxygen pressure. Moreover, integration with the underlying
subchondral bone remains an issue.
Because of these drawbacks, researchers have attempted to
engineer OC tissue that can seamlessly integrate with the
underlying subchondral bone. This can be accomplished ei-
ther by engineering amonophasic cartilage construct and then
relying on the native local environment to drive ossification
at the bone interface or by engineering a bone–cartilage
construct that contains both tissues before implantation.
Monophasic cartilage TE approaches have been applied
widely. For example, Koga et al. created cartilage using
synovium-derived MSCs. When implanted in a rabbit
model, MSCs produced extensive cartilage matrix, while
cells adjacent to the subchondral bone differentiated into
osteoblasts.37 However, such endogenous processes are
uncontrolled, and movement of the tidemark, the interface
between the bone and the cartilage, has been observed.
Therefore, others have attempted to create OC constructs
that contain either bone and cartilage or bone, cartilage, and
an interfacial region. Engineering a single construct that
contains bone and cartilage, however, remains challenging
because of the tissues’ distinct compositions, architectures,
and cellular microenvironments. One strategy to address
this is to create biphasic scaffolds formed from separate
osteogenic and chondrogenic constructs that are later com-
bined. Such strategies have been tested in vitro38 and in
large animal models.39 However, unlike in native OC tissue
in which a calcified hypertrophic zone exists between the
bone and cartilage, in many biphasic scaffolds, an abrupt
artificial interface may form, which may impact the con-
struct’s mechanical integrity. For example, when Grayson
et al. synthesized a biphasic construct by placing agarose
within a decellularized bone scaffold, they reported the
absence of a hypertrophic transition zone.40
Researchers have also attempted to form triphasic scaf-
folds, which contain an interfacial region between the car-
tilage and bone scaffolds, to more faithfully recapitulate the
native OC interface. For example, Da et al. formed a
compact interfacial layer by placing poly(lactic-co-glycolic
acid)-b-tricalcium phosphate between the chondrogenic and
bony components of a biphasic scaffold. They observed
enhanced mechanical properties in the interface-containing
scaffolds compared with those that lacked the interfacial
region, as well as increased OC tissue regeneration in a
rabbit model.41 Similarly, Kon et al. formed triphasic scaf-
folds by varying the ratios of type I collagen and hydroxy-
apatite in their constructs. When tested in 15 patients with
cartilage lesions, they were able to demonstrate safety and
short-term follow-up appeared promising.42 Nevertheless,
like biphasic scaffolds, triphasic scaffolds may still not fully
recapitulate the native tissue’s seamless interface and thus
may separate in vivo. This has been observed in poly-
caprolactone/alginate scaffolds upon subcutaneous implanta-
tion in a rat model, where the osteogenic and chondrogenic
portions often became separated.43 Moreover, biphasic and
triphasic scaffolds may require separate chondrogenic and
osteogenic culture conditions, which may create logistical
challenges for their scale-up and clinical use.
Alternatives to multiphasic scaffolds are continuous OC
scaffolds designed to enable synchronous formation of both
cartilage and bone with a seamless transition, mimicking the
calcified hypertrophic interface in native OC tissue. Con-
tinuous scaffolds may also preclude the need for separate
culture conditions as they can be designed to differentiate a
single progenitor population down different lineages de-
pending on location within the biomaterial construct. For
example, Harley et al. created continuous OC scaffolds by
lyophilizing mineralized and unmineralized type I collagen–
glycosaminoglycan suspensions to form a natural inter-
face.44 Researchers have also achieved continuous scaffolds
by creating morphogen gradients. For example, Wang et al.
utilized BMP2 and IGF-1-containing microspheres to create
inverse gradients in alginate hydrogels and observed corre-
sponding differentiation of encapsulated human MSCs
(hMSCs) down chondrogenic and osteogenic lineages.45
Similarly, Mohan et al. utilized inverse gradients of mi-
crospheres containing BMP2 and TGF-b1. When implanted
in a rat femoral defect model, they showed region-specific
regeneration of cartilage and bone and formation of a stable
interface.46
Exploiting the HIF-1a Regulatory Network for OC TE
As oxygen gradients form during OC tissue development
and aid in the maintenance of OC tissue in the adult, con-
trolling oxygen pressure may be an effective strategy to
engineer OC tissue. Researchers have described strategies to
locally regulate oxygen pressure in situ within biomaterials.
For example, oxygen-releasing molecules such as per-
fluorocarbons47 and hemoglobin48 or myglobin49 can be
incorporated into biomaterials to increase local oxygen
levels, using strategies amenable for OC TE. Similarly,
manganese dioxide nanoparticles50 and calcium peroxide51
can be used to generate oxygen within a TE construct. Al-
ternatively, oxygen scavengers can mediate the opposite
effect and lower local levels of oxygen. Indeed, it is possible
to locally decrease the oxygen pressure within a biomaterial
either by incorporating various molecules52 or simply by
limiting oxygen diffusion, which has been shown to stim-
ulate the chondrogenesis of progenitor cells.53
However, regulating oxygen itself may not be ideal as
hypoxia is also known to cause oxidative stress, prompt
potentially undesirable effects on cell metabolism, and
negatively impact cell growth and viability,54 all of which
may be detrimental to forming tissue. An alternative ap-
proach is to stabilize HIF-1a under normoxic conditions as
this has the potential to provide the beneficial prochondro-
genic effects of hypoxia, but in a more controlled and po-
tentially less deleterious manner. Indeed, as stabilization
of HIF-1a enhances the chondrogenic differentiation of
progenitor cells,55 minimizes chondrocyte hypertrophy, and
stimulates the production of cartilage-like ECM, manipu-
lating its regulatory network within TE scaffolds may be an
effective strategy to engineer OC tissue. A number of com-
pounds have been reported to ectopically stabilize HIF-1a
at normoxia and thus stimulate cellular responses that mimic
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those elicited by low oxygen pressure. Therefore, by incor-
porating these HIF mimetics into the chondrogenic region of
a TE scaffold, it may be possible to stimulate progenitor cells
to undergo region-specific formation of articular cartilage
(Fig. 3). To accomplish this, appropriate components of the
HIF complex that can be targeted pharmacologically need to
be recognized and compounds that act against them identi-
fied and incorporated into scaffolds.
Regulation of the HIF Transcriptional Complex
The a subunit of HIF exists in two forms—HIF-1a and
HIF-2a—both of which play roles in the regulation of car-
tilage formation. Knockout of HIF-1a results in cell death
and cartilage catabolism in the developing limb bud mes-
enchyme,2,56 and suppression of HIF-1a negatively impacts
the production of cartilage-associated matrix proteins in
cultured chondrocytes. HIF-2a, on the other hand, regulates
endochondral ossification by mediating angiogenesis and
ossification of the cartilage template56 and plays important
roles in cartilage degradation during OA.57 Therefore, be-
cause of HIF-1a’s central role in maintaining the chondrocyte
phenotype and cartilage ECM,30 it is the more obvious target
for OC TE strategies.
Central to regulation of HIF-1a is the prolyl hydroxylase
2–von Hippel-Lindau (PHD2-VHL) signaling cascade58
(Fig. 4). At normoxia, PHD2 utilizes molecular oxygen and
other cofactors to hydroxylate residues on the oxygen-
dependent degradation domain (ODDD) of HIF-1a.59 The
hydroxylated residues then serve as recognition motifs by
the VHL tumor suppressor protein. As part of the E3 ubi-
quitin ligase complex, VHL binds and ubiquitinates the
hydroxylated residues of HIF-1a, targeting the molecule for
degradation by the proteasome.60–62 However, under hyp-
oxic conditions, PHD2’s ability to hydroxylate HIF-1a is
diminished, enabling its cytosolic accumulation and nuclear
translocation, where together with transcriptional cofactors,
it activates expression of its target genes in the HIF com-
plex.63 Other pathways central to regulating HIF-1a degra-
dation are RACK1 and HSP90. HSP90 normally binds to
HIF-1a, thus preventing its degradation. However, RACK1
can compete with HSP90 in its binding to HIF-1a and, in
doing so, recruits the same ubiquitinating complex utilized
by VHL, thereby resulting in PHD2/VHL-independent HIF-
1a degradation.64–66
In addition to the PHD2-VHL pathway, HIF-1a also re-
quires cofactors to be recruited to the HIF transcriptional
complex to activate gene expression when bound to the
HRE in target gene promoters. Two important factors in this
complex are p300 and the CREB-binding protein (CBP).67
One key residue on HIF-1a involved in its binding with
p300/CBP is asparagine-803 (Asn-803).8 Indeed, Asn-803 is
also the target of another 2-oxoglutarate (2-OG)-utilizing
hydroxylase, factor inhibiting HIF (FIH), which similarly
regulates HIF transcriptional activity.8 FIH hydroxylates
Asn-803 on HIF-1a, preventing the binding of p300/CBP to
HIF-1a, and therefore disrupts the formation of a functional
HIF transcriptional complex.8
Harnessing the HIF Pathway for OC TE
by Stabilizing HIF-1a
Over the past two decades, there has been tremendous
interest in identifying compounds that are able to stabilize
HIF-1a and enhance its binding by transcriptional cofactors
at normoxia (Fig. 5) for potential use as therapeutic agents
to treat a range of conditions. The most common HIF mi-
metics include dimethyloxalylglycine (DMOG), desfer-
rioxamine (DFX), and cobalt chloride (CoCl2), all of which
target PHD2 and/or FIH.68,69 By targeting PHD2 and FIH,
HIF mimetics reduce HIF-1a’s prolyl and asparagine hy-
droxylation, reducing its subsequent degradation, and en-
hance its binding by transcriptional cofactors. DMOG acts
through competition with 2-OG by engaging the binding
pocket of the prolyl hydroxylase active site on both FIH
and PHD2.70 DFX is an iron chelator and sequesters
available Fe2+, which is required by both FIH and PHD2,
thereby reducing their activity.71 CoCl2, on the other hand,
may directly compete with Fe2+ binding to the PHD2 ac-
tive site.72
FIG. 3. Exploiting the HIF pathway in OC TE. An example of a progenitor-seeded biomaterial scaffold containing a
gradient of an HIF-1a-stabilizing compound. During differentiation and tissue formation, the differential levels of the HIF-
1a-stabilizing agent promote a continuous interface that mimics that in native OC tissue. The resulting continuous OC
construct would then contain spatially restricted regions of articular cartilage and subchondral bone. TE, tissue engineering.
Color images are available online.
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Recent work to compare how DFX, DMOG, and CoCl2
impact hMSC chondrogenesis in vitro showed that DMOG
upregulated expression of HIF target genes and induced a
more chondrogenic transcriptional profile compared with either
DFX or CoCl2.
55 These observations suggest that hMSC
chondrogenesis may be regulated bymechanismswith a greater
dependence on 2-OG than Fe2+ availability and suggest that
compounds that target 2-OGmay be more effective for OC TE.
These findings are supported by observations that cobalt, when
released from a bioactive glass, reduces hMSC chondrogenic
differentiation despite stabilizing HIF-1a.73 Sathy et al. have
since exploited the hypoxia-mimicking properties of DMOG
for cartilage TE by placing it within porcine-MSC-laden algi-
nate hydrogels. They showed that DMOG-containing con-
structs enhanced MSC chondrogenesis in vitro and cartilage-
like tissue formation in vivo.74 However, the HIF mimetic type,
specificity, concentration, and duration of exposure may also
play roles in their efficacy in promoting chondrogenesis, as
highlighted by conflicting results in the literature. Indeed, while
cobalt has been shown to promote chondrogenesis,75 others
have demonstrated that it inhibits chondrogenesis73 and that
this may be dependent on cell source.76
Nevertheless, although promising, the three most widely
tested HIF mimetics lack a high degree of specificity for
PHD2 FIH. Indeed, DMOG may also target similarly
structured enzymes that are essential for formation of the
collagen triple helix.77 Similarly, chelating Fe2+ ions or
displacing them in enzymatic reactions lends a poor degree of
control as iron is central in a range of other vital biological
processes, including the mitochondrial respiratory chain or
PHDs involved in collagen synthesis.78 More recently,
screens have identified additional 2-OG inhibitors,79 includ-
ing Kreb’s cycle metabolites80,81 and metal chelators,82 some
of which have been tested in clinical trials.83 GSK360A, for
example, has been shown to improve ventricular remodeling
following myocardial infarction,84 and FibroGen’s FG-2216
alleviates erythropoietin deficiency in various anemic condi-
tions.85 It will be particularly interesting to learn how these
compounds influence cell behavior in OC TE applications.
Alternative approaches can also be used to ectopically
stabilize HIF-1a by targeting the PHD2-VHL pathway. For
example, high-density lipoproteins (HDLs) enhance HIF-
dependent VEGF signaling through regulation of HIF-1a post-
translational modification.86,87 HDLs act through activation of
FIG. 4. The PHD2-VHL signaling cascade: an opportunity to regulate the HIF pathway. In response to molecular oxygen (O2),
FIH and PHD2 (in the presence of Fe2+, 2-OG, and ascorbate) hydroxylate specific amino acid residues on HIF-1a. FIH-mediated
hydroxylation blocks cofactors CBP/p300 from binding to HIF-1a, thereby reducing HIF transcriptional activity. PHD2-mediated
hydroxylation results in ubiquitination of the ODDD domain of HIF-1a by the VHL component of the ECV (elongin/culin/VHL)
ubiquitin ligase complex, thus promoting degradation of HIF-1a in the 265 proteasome and reducing HIF transcriptional activity.
Under hypoxic conditions, PHD2 and FIH activity are reduced, thus enabling HIF-1a to translocate and accumulate in the
nucleus, where it activates expression of HIF target genes in the HRE as part of a transcriptional complex with HIF-1b, CBP/
p300, and other cofactors. A negative feedback mechanism exists in which PHD2 expression is also enhanced by HIF activity.
CBP, CREB-binding protein; FIH, factor inhibiting HIF; 2-OG, 2-oxoglutarate; ODDD, oxygen-dependent degradation domain;
PHD2-VHL, prolyl hydroxylase 2–von Hippel-Lindau. Color images are available online.
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the ubiquitin ligase Siah2,88 which (when active) inhibits
PHD2/PHD3, leading to HIF-1a accumulation.87,89 PHD2/FIH
inhibitors designed to mimic cofactors that act with hydroxy-
lases or interfering RNA molecules are promising tools in this
regard as they can specifically target PHD2 and FIH. Indeed,
RNAi against PHD228,90 and native hypoxia-driven micro-
RNA91,92 have been shown to enhance HIF-1a stabilization.
Nitric oxide (NO) has also been implicated as a regulator
of HIF-1a,93 an effect that can also be induced by NO donors
such as GSNO, SNAP, NAC, and DetaNONOATE, which
similarly increase intracellular HIF-1a levels.94 These com-
pounds modify the HIF-1a ODDD through N-nitrosylation
and, in doing so, block VHL binding and subsequent HIF-1a
ubiquitination.95,96 GSNO has also been shown to inhibit
FIG. 5. Pharmacological strategies to manipulate the HIF pathway. (A) High-density lipoproteins regulate HIF-1a levels
through activation of Siah2, an E3 ubiquitin ligase, which targets PHD2 for proteasomal degradation. (B) Blocking binding
of the VHL component of the E3 ubiquitin ligase to HIF-1a, following its proline hydroxylation, reduces ubiquitination and
degradation. This can be achieved by molecules that bind and occupy the HIF-1a binding site of VHL or through the use of
nitric oxide donors, which chemically modify VHL or the ODDD of HIF-1a. (C) HIF-1a hydroxylation reactions can be
inhibited to reduce the subsequent ubiquitination and degradation of HIF-1a. For example, hydroxylation can be inhibited by
specific hydroxylase inhibitors such as cofactor analogs, agents that sequester the Fe2+ that is required at the hydroxylase active
sites, or ROS, which downregulate expression of PHD2. (D) HIF hydroxylases are susceptible to downregulation at the
transcriptional level by interfering RNA molecules, which reduce their translation and thus HIF-1a hydroxylation. Asn803,
asparagine-803; pro564/pro402, proline564/proline402; ROS, reactive oxygen species. Color images are available online.
HARNESSING HIF-1a FOR OSTEOCHONDRAL TISSUE ENGINEERING 7
PHD2 and FIH activity, at least in part, by blocking the
binding of Fe2+ to the active site, leading to similar levels of
HIF-1a stabilization as those observed in CoCl2-treated cell
cultures.97,98 SNAP similarly promotes HIF-dependent gene
expression by inhibiting VHL-HIF-1a binding and FIH ac-
tivity,99 and NAC has been shown to mimic the physiological
effect of chronic hypoxia in murine, vascular, pulmonary
endothelial cells through nitrosylation of proteins in the
PHD2/VHL pathway.100 Nevertheless, like the HIF mimet-
ics, targeting NO for OC TE is not specific as NO has a
variety of biological roles.
Researchers have also attempted to target the HIF-1a-
regulating effects of VHL.101 Peptides that mimic the hy-
droxylated ODDD of HIF-1a compete with native HIF-1a to
bind to VHL, reducing HIF-1a ubiquitination.102,103 This is
a particularly promising approach for OC TE as the peptide-
based inhibitors can be highly specific. Calcium signaling is
also a potential target. A calcium ionophore, which facili-
tates Ca2+ entry into the cell, has been shown to inhibit
dimerization and activation of RACK1, thereby inhibiting
its role in HIF-1a degradation.104 An alternative to reducing
HIF-1a degradation is augmenting HIF-1a translation. Cal-
cium ionophores or a calcium compound may tap into cal-
cium’s role in HIF-1a translation. However, the use of factors
that enhance HIF-1a translation may be most effective when
used in combination with those that inhibit HIF-1a degra-
dation to increase overall levels of HIF-1a and increase bi-
ological function of the HIF transcriptional complex.
Outlook
As hypoxia plays fundamental roles in development and
maintenance of OC tissue, attempting to mimic its effects on
progenitor cells may be an effective means to engineer OC
tissue. Indeed, a biomaterial that is able to spatially control the
intracellular stabilization and cofactor binding of HIF-1a may
stimulate region-specific formation of articular cartilage where
HIF-1a is active, while promoting the formation of a sub-
chondral bone region where HIF-1a activity is depleted, all
within a single construct cultured under normoxic conditions.
Stabilization of HIF-1a at normoxia can be achieved by using
HIF mimetics such as DMOG, DFX, and CoCl2. However,
targeting the native regulatory signaling pathways that con-
trol intracellular levels of HIF-1a, such as the ODDD domain
of HIF-1a, using peptides or RNAi may be an even more
effective means to control intracellular levels of HIF-1a.
UtilizingHIFmimetics for OCTEwill likely require them to
be stably incorporated into scaffolds in a regional or gradient
manner and for their controlled release. This could be achieved
by tethering HIF mimetics directly to the scaffold or by incor-
porating soluble factorswithin degradablemicrospheres, whose
locations within the scaffold are spatially controlled.45 Light-
based chemistries could also be used to locally attach a HIF
mimetic to a scaffold by applying differential levels of UV light
along the length of a presynthesized biomaterial.105 Indeed,
strategies to achieve localized delivery of HIF mimetics are
already within reach and thus can be quickly incorporated into
OC TE designs with the potential to deliver on the promise of
OC TE to repair cartilage lesions and prevent OA.
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